Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
iTeos Therapeutics Inc is a biotechnology business based in the US. iTeos Therapeutics shares (ITOS) are listed on the NASDAQ and all prices are listed in US Dollars. iTeos Therapeutics employs 78 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$26.99|
|52-week range||$17.43 - $47.61|
|50-day moving average||$27.41|
|200-day moving average||$25.08|
|Wall St. target price||$49.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-2.28%|
|1 month (2021-09-27)||-0.55%|
|3 months (2021-07-27)||12.88%|
|6 months (2021-04-27)||15.05%|
|1 year (2020-10-26)||14.90%|
|2 years (2019-10-23)||N/A|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-20.6%|
|Return on equity TTM||-31.04%|
|Market capitalisation||$964 million|
TTM: trailing 12 months
There are currently 789,317 iTeos Therapeutics shares held short by investors – that's known as iTeos Therapeutics's "short interest". This figure is 12% up from 704,604 last month.
There are a few different ways that this level of interest in shorting iTeos Therapeutics shares can be evaluated.
iTeos Therapeutics's "short interest ratio" (SIR) is the quantity of iTeos Therapeutics shares currently shorted divided by the average quantity of iTeos Therapeutics shares traded daily (recently around 154768.03921569). iTeos Therapeutics's SIR currently stands at 5.1. In other words for every 100,000 iTeos Therapeutics shares traded daily on the market, roughly 5100 shares are currently held short.
However iTeos Therapeutics's short interest can also be evaluated against the total number of iTeos Therapeutics shares, or, against the total number of tradable iTeos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iTeos Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 iTeos Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0392% of the tradable shares (for every 100,000 tradable iTeos Therapeutics shares, roughly 39 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against iTeos Therapeutics.
Find out more about how you can short iTeos Therapeutics stock.
We're not expecting iTeos Therapeutics to pay a dividend over the next 12 months.
Iteos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.